Searched for
INGELHEIM
Boehringer Ingelheim, Viyash Scientific enter pet healthcare pact in IndiaGerman biopharma giant Boehringer Ingelheim is partnering with Viyash Scientific to bring its pet healthcare products to India. This collab...- Lupin shares in focus on acquisition of 3 anti-diabetes trademarks to strengthen diabetes portfolioLupin Share Price: Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster ...
- Lupin acquires two diabetes brands from Boehringer IngelheimLupin has been marketing Ondero and Ondero Met since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelhei...
- Boehringer Ingelheim appoints Gagandeep Singh as MD, Head of Human Pharma IndiaBoehringer Ingelheim on Monday said that the company has appointed Gagandeep Singh as Managing Director and Head of Human Pharma India, eff...
- Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drugBI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making,...
- Boehringer Ingelheim gets CDSCO nod for Jardiance to treat for new heart failure indicationJardiance is the top selling drug of BI in India, used in treatment of type-2 diabetes and for the treatment of heart failure with reduced ...
- Boehringer Ingelheim India seeks system to keep tab on patent infringementIn terms of focus areas in the country, she said the drug firm is focussed on providing solutions for non communicable diseases like diabet...
- Lupin Q1 results: Net profit jumps 5-fold to Rs 542 croreThe significant jump in June quarter net profit was on account of robust sales and income received from biopharmaceutical firm Boehringer I...
- Lupin receives $50 million from Boehringer Ingelheim for achievement of key milestonesIn a regulatory filing Lupin announced "the achievement of key milestones for Lupin's MEK inhibitor compound (LNP3794) that is planned for ...
- Sanofi, Boehringer Ingelheim close business swap in IndiaSanofi is excited to embrace the incoming CHC brands and people associated with this business, as this is in line with objective of boostin...
- Boehringer Ingelheim hid key info in petition, says GennovaGennova’s stroke medicine — tenecteplase — was approved by an expert committee of the Central Drugs Standard Control Organisation (CDSCO) i...
- Action between Boehringer Ingelheim and Gennova over stroke medicine moves to courtThe approval of tenectaplase for use in stroke patients has been a point of contention between German drug maker Boehringer Ingelheim and G...
- German giant Boehringer Ingelheim battles India's Gennova Biopharma over stroke treatmentGennova recently secured marketing authorisation of tenectaplase for stroke patients in India, the first such use of the drug anywhere in t...
- Sanofi, Boehringer Ingelheim seek CCI nod for $25-billion global asset swap dealThe commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition.
- Boehringer Ingelheim not for immuno therapy drugsA patient of a recently introduced immuno therapy drug is former US President Jimmy Carter who was treated with the drug Keytruda of Merck ...
- Lupin, Boehringer Ingelheim to co-market anti-diabetes drug linagliptin in IndiaBoehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combina...
- Zydus Cadila loses two popular brandsDulcolax and Buscopan had been present for the past many decades in India, initially through an agreement that Boehringer Ingelheim had wit...
- Eli Lilly aims to be among top 20 pharma companies in India by 2020The company lays maximum emphasis on its diabetes portfolio and would be introducing new products to cater to over 60 million patients in t...
- Boehringer Ingelheim, Eli Lilly launch Linagliptin tabletsBoehringer Ingelheim India and Eli Lilly and Company India (Lilly) today said they have launched Linagliptin tablets used for treating diab...
- Ranbaxy, Astellas end patent rowRanbaxy Laboratories has reached an out-of-court settlement with Japanese company Astellas and Boehringer Ingelheim to sell Flomax, a drug ...
Load More
